Welcome to our dedicated page for Hcw Biologics SEC filings (Ticker: HCWB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
HCW Biologics Inc. filings document a clinical-stage biopharmaceutical issuer developing fusion immunotherapeutics through the TOBI and TRBC platforms. Its SEC records include 8-K reports for operating results, clinical and regulatory program updates, material agreements, licensing activity and Nasdaq-related corporate events, along with registration statements covering securities offerings and related capital-structure disclosures.
HCWB proxy and governance filings describe annual meeting matters, shareholder voting procedures and bylaw amendments, including quorum provisions. The company’s formal disclosures also address product-candidate development, financial condition, emerging growth company status, risk factors, ownership and governance controls relevant to its public-company reporting profile.
HCW Biologics Inc. received a decision from a Nasdaq Hearings Panel granting more time to regain compliance with Nasdaq’s minimum bid price requirement. The company had previously fallen below the $1 per share minimum bid price under Nasdaq Listing Rule 5550(a)(2) after already completing a 1-for-40 reverse stock split on April 11, 2025.
The Panel is allowing the company to remain listed if it achieves a bid price of at least $1 per share for twenty consecutive trading days on or before July 29, 2026. The Panel indicated that if the company again becomes deficient with the bid price rule before September 22, 2026, it will be immediately delisted.
If HCW Biologics satisfies the conditions and regains compliance, the Panel intends to place the company under a Discretionary Panel Monitor for an additional one-year period, adding ongoing oversight of its listing status.
HCW Biologics Inc. director and Chief Executive Officer Hing C. Wong reported significant personal purchases of the company’s securities. On May 22, he bought 113,879 shares of Common Stock at $1.405 per share and acquired Common Stock Purchase Warrants for another 113,879 underlying shares with a $1.28 exercise price, both directly from the issuer in a private placement. Following these transactions, he directly owns 615,790 shares of Common Stock and 118,110 warrants, increasing his overall economic exposure to the company.
HCW Biologics Inc. director T. Scott Garrett, through an LLC, reported net buying activity in both common shares and warrants. The LLC acquired 177,936 shares of common stock at $1.405 per share in a private placement directly from the issuer, which the footnote states is exempt from Section 16(b) under Rule 16b-3(d). Following this transaction, indirect holdings of common stock rose to 203,441 shares. The LLC also acquired 177,936 Common Stock Purchase Warrants with an exercise price of $1.28 per share, expiring on November 22, 2031, increasing indirect warrant holdings to 180,628. In total, the filing shows 355,872 shares’ worth of net buy-side exposure added across stock and warrants.
HCW Biologics Inc. Chief Financial Officer Rebecca Byam bought additional equity in the company on May 22, 2026. She purchased 14,235 shares of common stock at an average price of $1.405 per share, increasing her direct common stock holdings to 57,245 shares.
Byam also acquired a Common Stock Purchase Warrant for 14,235 underlying shares with a conversion price of $1.28 per share, expiring on November 22, 2031, bringing her directly held warrants to 18,466. According to the filing, these securities were purchased directly from the issuer in a private placement exempt from Section 16(b) under Rule 16b-3(d).
HCW Biologics Inc. terminated its exclusive worldwide license with Wugen Inc. for ex vivo rights to its HCW9206 and HCW9201 molecules and regained full ex vivo rights to both reagents. The company acquired these rights for no cost and retained the upfront license consideration, including 2.2 million shares of Wugen common stock.
HCW Biologics believes recent peer-reviewed data suggest HCW9206 may help manufacture more persistent, functional CAR-T cells and memory-like NK cells, potentially lowering production costs. The company plans to commercialize these reagents through partnerships with CAR-T and NK-cell therapy developers and manufacturers.
HCW Biologics Inc. entered into a private placement financing, selling 2,846,975 units at $1.405 per unit for aggregate gross proceeds of approximately $4.0 million. Each unit includes one share of common stock (or a pre-funded warrant) and one common warrant to buy an additional share.
At closing, the company issued 427,046 shares, 2,419,929 pre-funded warrants, and common warrants to purchase up to 2,846,975 shares of common stock. The common warrants have a $1.28 exercise price and a five-and-a-half-year term, while pre-funded warrants are exercisable at $0.0001 per share and have no expiration.
The company plans to use net proceeds to continue clinical trials for HCW9302, advance IND-enabling studies for T-cell engager HCW11-018b and immune checkpoint inhibitor HCW11-040, as well as for general corporate purposes and repayment of certain debts and settlements. Investor ownership is capped through 9.99% and 4.99% beneficial ownership limitations on warrant exercises.
HCW Biologics Inc. is offering up to 4,590,164 shares of Common Stock (or pre-funded warrants in lieu thereof) for gross proceeds of up to $5,600,000 in a post-effective amendment to its Form S-1. The amendment incorporates the Company’s Form 10-Q for the quarter ended March 31, 2026 and extends the offering termination date to May 22, 2026. The prospectus states the offering will be conducted on a reasonable best efforts basis with E.F. Hutton & Co. as exclusive placement agent and that certain directors and officers intend to purchase a combined $430,000 of securities on the same terms as other investors. The filing discloses Nasdaq continued-listing correspondence, including a recent bid-price deficiency notice and a May 5, 2026 hearing before a Nasdaq Hearings Panel; the Company awaits the Panel’s determination.
HCW Biologics Inc. ownership disclosure: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 353,680 shares of Common Stock, representing 4.99% of the class. The filing states Armistice Capital exercises shared voting and dispositive power over these shares through its role as investment manager. The filing is signed May 15, 2026.
HCW Biologics Inc. reported a sharp turnaround for the three months ended March 31, 2026, driven by a major licensing deal. Net revenues rose to $6,531,930 from $1,013 a year earlier, largely from a Trimmune license that generated $6.5 million of revenue.
The company moved from a net loss of $2,196,875 to net income of $3,472,480, with net income attributable to common stockholders of $1,984,008, or $0.37 per share. Total assets increased to $27,342,213, including an investment in Trimmune and Wugen.
Despite the profitable quarter, management discloses cumulative net losses of $102.3 million, low cash of $1,228,879, ongoing legal and debt obligations, and explicitly states that these factors raise substantial doubt about the company’s ability to continue as a going concern for at least 12 months.
HCW Biologics Inc. reported a sharp turnaround for the three months ended March 31, 2026, driven by a major licensing deal. Net revenues rose to $6,531,930 from $1,013 a year earlier, largely from a Trimmune license that generated $6.5 million of revenue.
The company moved from a net loss of $2,196,875 to net income of $3,472,480, with net income attributable to common stockholders of $1,984,008, or $0.37 per share. Total assets increased to $27,342,213, including an investment in Trimmune and Wugen.
Despite the profitable quarter, management discloses cumulative net losses of $102.3 million, low cash of $1,228,879, ongoing legal and debt obligations, and explicitly states that these factors raise substantial doubt about the company’s ability to continue as a going concern for at least 12 months.
HCW Biologics reported first quarter 2026 results showing a sharp swing to profitability driven by a new licensing deal. Revenue for the three months ended March 31, 2026 rose to $6.54 million from $5,065 a year earlier, largely from an exclusive worldwide license for HCW11-006 with Trimmune that generated a $3.5 million cash fee and a $3.5 million equity interest. Net income for the quarter improved to $3.47 million from a loss of $2.20 million, while net income attributable to common stockholders was $1.98 million, or $0.37 per share. Despite the stronger quarter, the company states there is “substantial doubt” about its ability to continue as a going concern over the next 12 months without additional funding, and it is appealing a Nasdaq decision to delist its shares for failing to meet the $1.00 minimum bid price requirement.
HCW Biologics reported first quarter 2026 results showing a sharp swing to profitability driven by a new licensing deal. Revenue for the three months ended March 31, 2026 rose to $6.54 million from $5,065 a year earlier, largely from an exclusive worldwide license for HCW11-006 with Trimmune that generated a $3.5 million cash fee and a $3.5 million equity interest. Net income for the quarter improved to $3.47 million from a loss of $2.20 million, while net income attributable to common stockholders was $1.98 million, or $0.37 per share. Despite the stronger quarter, the company states there is “substantial doubt” about its ability to continue as a going concern over the next 12 months without additional funding, and it is appealing a Nasdaq decision to delist its shares for failing to meet the $1.00 minimum bid price requirement.